世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

アジア太平洋地域の新生児スクリーニング市場の2030年までの予測 - 地域別分析 - 製品タイプ別(試薬およびアッセイキット、機器)、技術別(タンデム質量分析(TMS)、分子アッセイ、免疫アッセイおよび酵素アッセイ、パルスオキシメトリースクリーニング技術、その他)、検査タイプ別(乾燥血液スポット検査、聴覚スクリーニング検査、重症先天性心疾患(CCHD)検査、その他)、エンドユーザー別(病院および診療所、診断研究所)


Asia Pacific Newborn Screening Market Forecast to 2030 - Regional Analysis - by Product Type (Reagents and Assay Kits, and Instruments), Technology [Tandem Mass Spectrometry (TMS), Molecular Assays, Immunoassays and Enzymatic Assays, Pulse Oximetry Screening Technology, and Others], Test Type [Dry Blood Spot Test, Hearing Screen Test, Critical Congenital Heart Diseases (CCHD) Test, and Others], and End User (Hospitals and Clinics, and Diagnostic Laboratories)

アジア太平洋地域の新生児スクリーニング市場は、2022年には2億7,013万米ドルと評価され、2030年には6億214万米ドルに達すると予測されている。 新生児の遺伝子スクリーニングがアジア太平洋地域の新生児スク... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
The Insight Partners
ザ・インサイトパートナーズ
2024年2月7日 US$3,550
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
107 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

アジア太平洋地域の新生児スクリーニング市場は、2022年には2億7,013万米ドルと評価され、2030年には6億214万米ドルに達すると予測されている。

新生児の遺伝子スクリーニングがアジア太平洋地域の新生児スクリーニング市場を促進

病状の遺伝的原因に関する知識の深まりや医療技術の進歩に伴い、新生児の包括的な遺伝子スクリーニングの需要が高まっている。その結果、新生児スクリーニング市場の企業は、革新的で費用対効果の高いスクリーニング・ソリューションを開発している。YescartaとZyntegloは、大細胞型B細胞リンパ腫とβ-サラセミアに対する認可された遺伝子治療の2つの例である。さらに、出生時に疾患に対する遺伝的素因を特定する能力を付与する技術の出現は、個別化医療への道を開き、精密医療という広範な傾向と一致する。

妊娠中の遺伝性疾患のスクリーニングは、妊娠に関連する問題の早期発見にも重点を置いている。次世代シーケンサーは、すべての染色体における異数体(ダウン症候群やトリソミー21など)や部分的な染色体異常(重複や欠失)の検出において95%以上の感度で新生児の出生前スクリーニングを支援する。蛍光in-situハイブリダイゼーション(FISH)は、鎌状赤血球貧血のような単発性疾患を検出するために使用されます。母体血漿を用いた無細胞胎児DNAアプローチのような非侵襲的手順は、遺伝子検査における最近の進歩である。胚DNAはその大きさの違いから母体DNA片と区別することができる。蛍光プローブを用いたリアルタイムPCR、ショットガンシーケンス(SolexaまたはIllumina)、あるいは巨大なターゲットパラレルシーケンスを用いて、胎児の病状に関連するDNAを調べることができる。これにより、この種の遺伝子スクリーニングがさらに研究されれば、医師は特定の薬理療法(薬理遺伝学)による早期の分子的介入を行ったり、細胞、組織、臓器を物理的、化学的に変化させたりすることができるようになる。このように、乳児の遺伝性疾患スクリーニング方法の進歩は、新生児スクリーニング市場全体にとって計り知れない可能性を秘めている。

アジア太平洋地域の新生児スクリーニング市場概要

アジア太平洋地域の新生児スクリーニング市場は、中国、日本、インド、韓国、オーストラリア、その他のアジア太平洋地域に区分される。アジア太平洋地域の新生児スクリーニング市場は、日本、中国、インド、韓国、オーストラリア、その他のアジア太平洋地域に区分される。アジア太平洋地域は、2022年から2030年にかけて世界の新生児スクリーニング市場で最も急成長する地域となる見込みです。この地域における市場の成長予測は、新生児の出生数の多さ、先天性疾患の有病率の急上昇、新生児の先天性異常の早期診断に関する意識の高まり、新生児スクリーニングのためのより良いソリューションの提供に向けて活動している組織の存在と関連づけることができる。

アジア太平洋地域における新生児スクリーニングは牽引力を増しており、中国、インド、その他の国々の政府機関は、出生率の高さから新生児スクリーニング・プログラムを実施する必要がある。国連国際児童緊急基金(UNICEF)によると、インドでは1日に67,385人の赤ちゃんが誕生しており、1日に世界で記録される出産の6分の1を占めている。さらに、Worldmapperによると、2022年には2300万人、次いで中国の1000万人の赤ちゃんが誕生している。絶え間なく上昇する出生率に伴い、インドだけでなくアジア太平洋の他の国々でも乳幼児ケアへの注目が高まっている。

アジア太平洋地域の新生児スクリーニング市場の売上高と2030年までの予測(百万米ドル)

アジア太平洋地域の新生児スクリーニング市場のセグメンテーション

アジア太平洋地域の新生児スクリーニング市場は、製品タイプ、技術、検査タイプ、エンドユーザー、国によって区分されます。

製品タイプに基づき、アジア太平洋地域の新生児スクリーニング市場は試薬・アッセイキットと機器に二分される。試薬とアッセイキットセグメントは、2022年にアジア太平洋地域の新生児スクリーニング市場でより大きなシェアを占めた。試薬・アッセイキット分野はDNAベースアッセイ、免疫アッセイ、酵素アッセイに細分化される。機器セグメントは、新生児障害スクリーニング機器、パルスオキシメーター、新生児聴覚スクリーニング機器、その他の機器に細分化される。

技術面では、アジア太平洋地域の新生児スクリーニング市場は、タンデム質量分析(TMS)、分子アッセイ、免疫アッセイと酵素アッセイ、パルスオキシメトリースクリーニング技術、その他の技術に分類される。パルスオキシメトリースクリーニング技術セグメントは、2022年にアジア太平洋地域の新生児スクリーニング市場で最大のシェアを占めた。

検査タイプに基づき、アジア太平洋地域の新生児スクリーニング市場は、乾燥血液スポット検査、聴覚スクリーン検査、重症先天性心疾患(CCHD)検査、その他の検査タイプに分類される。2022年には、乾燥血液スポット検査分野がアジア太平洋地域の新生児スクリーニング市場で最大のシェアを占めた。

エンドユーザー別では、アジア太平洋地域の新生児スクリーニング市場は病院・診療所と診断研究所に区分される。病院・診療所セグメントは2022年にアジア太平洋地域の新生児スクリーニング市場でより大きなシェアを占めた。

国別では、アジア太平洋地域の新生児スクリーニング市場は、中国、日本、インド、オーストラリア、韓国、アジア太平洋地域以外に分類される。中国は2022年にアジア太平洋地域の新生児スクリーニング市場を支配した。

Bio-Rad Laboratories Inc、LifeCell International Pvt Ltd、Masimo Corp、Medtronic Plc、Natus Medical Inc、PerkinElmer Inc、Trivitron Healthcare Pvt Ltd、Waters Corpは、アジア太平洋地域の新生児スクリーニング市場で事業を展開している大手企業である。

ページTOPに戻る


目次

Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Newborn Screening Market - Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Surging Government Funding for Newborn Screening
4.1.2 Rising Burden of Congenital Diseases
4.1.3 Increasing Prevalence of Newborn Disorders
4.2 Key Market Restraints
4.2.1 Lack of Uniformity in Newborn Screening Policies and Practices
4.3 Key Market Opportunities
4.3.1 Genetic Screening of Newborns
4.4 Future Trends
4.4.1 Integration of Machine Learning and Artificial Intelligence in Screening
4.5 Impact Analysis:
5. Newborn Screening Market - Asia Pacific Market Analysis
5.1 Asia Pacific Newborn Screening Market Revenue (US$ Mn), 2022 - 2030
6. Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 - by Product Type
6.1 Overview
6.2 Asia Pacific Newborn Screening Market Revenue Share, by Product Type, 2022 & 2030 (%)
6.3 Reagents and Assay Kits
6.3.1 Overview
6.3.2 Reagents and Assay Kits: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Asia Pacific Newborn Screening Market, by Reagents and Assay Kits, 2020-2030 (US$ Million)
6.4 Instruments
6.4.1 Overview
6.4.2 Instruments: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Asia Pacific Newborn Screening Market, by Instruments, 2020-2030 (US$ Million)
7. Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 - by Technology
7.1 Overview
7.2 Asia Pacific Newborn Screening Market Revenue Share, by Technology 2022 & 2030 (%)
7.3 Tandem Mass Spectrometry (TMS)
7.3.1 Overview
7.3.2 Tandem Mass Spectrometry (TMS): Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Molecular Assays
7.4.1 Overview
7.4.2 Molecular Assays: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Immunoassays and Enzymatic Assays
7.5.1 Overview
7.5.2 Immunoassays and Enzymatic Assays: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Pulse Oximetry Screening Technology
7.6.1 Overview
7.6.2 Pulse Oximetry Screening Technology: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Other Technologies
7.7.1 Overview
7.7.2 Other Technologies: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 - by Test Type
8.1 Overview
8.2 Asia Pacific Newborn Screening Market Revenue Share, by Test Type 2022 & 2030 (%)
8.3 Dry Blood Spot Test
8.3.1 Overview
8.3.2 Dry Blood Spot Test: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Hearing Screen Test
8.4.1 Overview
8.4.2 Hearing Screen Test: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Critical Congenital Heart Diseases (CCHD) Test
8.5.1 Overview
8.5.2 Critical Congenital Heart Diseases (CCHD) Test: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Other Test Types
8.6.1 Overview
8.6.2 Other Test Types: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 - by End User
9.1 Overview
9.2 Asia Pacific Newborn Screening Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals and Clinics
9.3.1 Overview
9.3.2 Hospitals and Clinics: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Diagnostic Laboratories
9.4.1 Overview
9.4.2 Diagnostic Laboratories: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Newborn Screening Market - Country Analysis
10.1 Asia Pacific Newborn Screening Market, Revenue and Forecast to 2030
10.1.1 Overview
10.1.2 Asia Pacific Newborn Screening Market, by Country
10.1.2.1 China
10.1.2.1.1 China Newborn Screening Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.1.2 China: Newborn Screening Market, by Product Type, 2020-2030 (US$ Million)
10.1.2.1.2.1 China: Newborn Screening Market, For Reagents and Assay Kits by Product Type, 2020-2030 (US$ Million)
10.1.2.1.2.2 China: Newborn Screening Market, For Instruments by Product Type, 2020-2030 (US$ Million)
10.1.2.1.3 China: Newborn Screening Market, by Technology, 2020-2030 (US$ Million)
10.1.2.1.4 China: Newborn Screening Market, by Test Type, 2020-2030 (US$ Million)
10.1.2.1.5 China: Newborn Screening Market, by End User, 2020-2030 (US$ Million)
10.1.2.2 Japan
10.1.2.2.1 Japan Newborn Screening Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.2.2 Japan: Newborn Screening Market, by Product Type, 2020-2030 (US$ Million)
10.1.2.2.2.1 Japan: Newborn Screening Market, For Reagents and Assay Kits by Product Type, 2020-2030 (US$ Million)
10.1.2.2.2.2 Japan: Newborn Screening Market, For Instruments by Product Type, 2020-2030 (US$ Million)
10.1.2.2.3 Japan: Newborn Screening Market, by Technology, 2020-2030 (US$ Million)
10.1.2.2.4 Japan: Newborn Screening Market, by Test Type, 2020-2030 (US$ Million)
10.1.2.2.5 Japan: Newborn Screening Market, by End User, 2020-2030 (US$ Million)
10.1.2.3 India
10.1.2.3.1 India Newborn Screening Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.3.2 India: Newborn Screening Market, by Product Type, 2020-2030 (US$ Million)
10.1.2.3.2.1 India: Newborn Screening Market, For Reagents and Assay Kits by Product Type, 2020-2030 (US$ Million)
10.1.2.3.2.2 India: Newborn Screening Market, For Instruments by Product Type, 2020-2030 (US$ Million)
10.1.2.3.3 India: Newborn Screening Market, by Technology, 2020-2030 (US$ Million)
10.1.2.3.4 India: Newborn Screening Market, by Test Type, 2020-2030 (US$ Million)
10.1.2.3.5 India: Newborn Screening Market, by End User, 2020-2030 (US$ Million)
10.1.2.4 Australia
10.1.2.4.1 Australia Newborn Screening Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.4.2 Australia: Newborn Screening Market, by Product Type, 2020-2030 (US$ Million)
10.1.2.4.2.1 Australia: Newborn Screening Market, For Reagents and Assay Kits by Product Type, 2020-2030 (US$ Million)
10.1.2.4.2.2 Australia: Newborn Screening Market, For Instruments by Product Type, 2020-2030 (US$ Million)
10.1.2.4.3 Australia: Newborn Screening Market, by Technology, 2020-2030 (US$ Million)
10.1.2.4.4 Australia: Newborn Screening Market, by Test Type, 2020-2030 (US$ Million)
10.1.2.4.5 Australia: Newborn Screening Market, by End User, 2020-2030 (US$ Million)
10.1.2.5 South Korea
10.1.2.5.1 South Korea Newborn Screening Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.5.2 South Korea: Newborn Screening Market, by Product Type, 2020-2030 (US$ Million)
10.1.2.5.2.1 South Korea: Newborn Screening Market, For Reagents and Assay Kits by Product Type, 2020-2030 (US$ Million)
10.1.2.5.2.2 South Korea: Newborn Screening Market, For Instruments by Product Type, 2020-2030 (US$ Million)
10.1.2.5.3 South Korea: Newborn Screening Market, by Technology, 2020-2030 (US$ Million)
10.1.2.5.4 South Korea: Newborn Screening Market, by Test Type, 2020-2030 (US$ Million)
10.1.2.5.5 South Korea: Newborn Screening Market, by End User, 2020-2030 (US$ Million)
10.1.2.6 Rest of Asia Pacific
10.1.2.6.1 Rest of Asia Pacific Newborn Screening Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.6.2 Rest of Asia Pacific: Newborn Screening Market, by Product Type, 2020-2030 (US$ Million)
10.1.2.6.2.1 Rest of Asia Pacific: Newborn Screening Market, For Reagents and Assay Kits by Product Type, 2020-2030 (US$ Million)
10.1.2.6.2.2 Rest of Asia Pacific: Newborn Screening Market, For Instruments by Product Type, 2020-2030 (US$ Million)
10.1.2.6.3 Rest of Asia Pacific: Newborn Screening Market, by Technology, 2020-2030 (US$ Million)
10.1.2.6.4 Rest of Asia Pacific: Newborn Screening Market, by Test Type, 2020-2030 (US$ Million)
10.1.2.6.5 Rest of Asia Pacific: Newborn Screening Market, by End User, 2020-2030 (US$ Million)
11. Asia Pacific Newborn Screening Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in Newborn Screening Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 LifeCell International Pvt Ltd
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Trivitron Healthcare Pvt Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 PerkinElmer Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Waters Corp
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Bio-Rad Laboratories Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Masimo Corp
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Natus Medical Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Medtronic Plc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

 

ページTOPに戻る


 

Summary

The Asia Pacific newborn screening market was valued at US$ 270.13 million in 2022 and is expected to reach US$ 602.14 million by 2030; it is estimated to grow at a CAGR of 10.5% from 2022 to 2030.

Genetic Screening of Newborns Fuels the Asia Pacific Newborn Screening Market.

The demand for comprehensive genetic screening of newborns is rising with the deepening knowledge about the genetic causes of medical conditions and advancements in healthcare technologies. As a result, companies in the newborn screening market are developing innovative, cost-effective screening solutions. Yescarta and Zynteglo are two examples of authorized gene treatments for large B-cell lymphoma and beta-thalassemia. Further, the emergence of technologies conferring an ability to identify genetic predispositions to diseases at birth pave the way for personalized healthcare, aligning with the broader trend of precision medicine.

Screening for genetic diseases during pregnancy also focuses on the early detection of pregnancy-related problems. Next-generation sequencing aids in the prenatal screening of neonates with a sensitivity of above 95% for detecting aneuploidies (such as Down syndrome and Trisomy 21) or partial chromosomal abnormalities (duplications or deletions) in all chromosomes. Fluorescence in-situ hybridization (FISH) is employed to detect monogenic illnesses such as sickle cell anemia; it also aids in an effective preimplantation genetic diagnosis. Noninvasive procedures such as the cell-free fetal DNA approach using maternal plasma are the recent advancements in genetic tests. The embryonic DNA can be distinguished from maternal DNA pieces based on differences in their sizes. Real-time PCR with fluorescent probes, shotgun sequencing (Solexa or Illumina), or huge targeted parallel sequencing can be used to examine DNA associated with fetal medical conditions. This would allow doctors to provide early molecular interventions with certain pharmacological therapies (pharmacogenetics) and to transform cells, tissues, and organs physically and chemically if this type of genetic screening is further researched. Thus, advancements in methods for screening infants for genetic disorders hold immense potential for the overall newborn screening market.

Asia Pacific Newborn Screening Market Overview

The newborn screening market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The Asia -Pacific newborn screening market is segmented into Japan, China, India, South Korea, Australia, and the Rest of Asia -Pacific. Asia -Pacific is expected to be the fastest-growing region in the global newborn screening market during 2022-2030. The projected growth of the market in this region can be associated with the high number of newborn births, the soaring prevalence of congenital diseases, rising awareness regarding early diagnosis of birth defects in newborns, and the presence of organizations working toward offering better solutions for newborn screening.

Screening of newborns in Asia -Pacific is gaining traction; government agencies in China, India, and other countries need to implement newborn screening programs owing to the high birth rate. According to the United Nations International Children's Emergency Fund (UNICEF), 67,385 babies are born in India each day, accounting for one-sixth of childbirths recorded globally in a day. In addition, India has become the most populated nation; as per Worldmapper, ~23 million babies were born in 2022, followed by China with the birth of 10 million babies. With the constantly soaring birth rate, the focus on infant care is increasing in India, as well as in other countries in Asia -Pacific.

Asia Pacific Newborn Screening Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Newborn Screening Market Segmentation

The Asia Pacific newborn screening market is segmented based on product type, technology, test type, end user, and country.

Based on product type, the Asia Pacific newborn screening market is bifurcated into reagents and assay kits, and instruments. The reagents and assay kits segment held a larger Asia Pacific newborn screening market share in 2022. The reagents and assay kits segment is subsegmented into DNA-based assays, and immunoassays and enzymatic assays. Instruments segment is subsegmented into newborn disorder screening instruments, pulse oximeters, newborn hearing screening instruments, and other instruments.

In terms of technology, the Asia Pacific newborn screening market is categorized into tandem mass spectrometry (TMS), molecular assays, immunoassays and enzymatic assay, pulse oximetry screening technology, and other technologies. The pulse oximetry screening technology segment held the largest Asia Pacific newborn screening market share in 2022.

Based on test type, the Asia Pacific newborn screening market is categorized into dry blood spot test, hearing screen test, critical congenital heart diseases (CCHD) test, and other test types. The dry blood spot test segment held the largest Asia Pacific newborn screening market share in 2022.

By end user, the Asia Pacific newborn screening market is segmented into hospitals and clinics and diagnostic laboratories. The hospitals and clinics segment held a larger Asia Pacific newborn screening market share in 2022.

Based on country, the Asia Pacific newborn screening market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific newborn screening market in 2022.

Bio-Rad Laboratories Inc, LifeCell International Pvt Ltd, Masimo Corp, Medtronic Plc, Natus Medical Inc, PerkinElmer Inc, Trivitron Healthcare Pvt Ltd, and Waters Corp are some of the leading companies operating in the Asia Pacific newborn screening market.



ページTOPに戻る


Table of Contents

Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Newborn Screening Market - Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Surging Government Funding for Newborn Screening
4.1.2 Rising Burden of Congenital Diseases
4.1.3 Increasing Prevalence of Newborn Disorders
4.2 Key Market Restraints
4.2.1 Lack of Uniformity in Newborn Screening Policies and Practices
4.3 Key Market Opportunities
4.3.1 Genetic Screening of Newborns
4.4 Future Trends
4.4.1 Integration of Machine Learning and Artificial Intelligence in Screening
4.5 Impact Analysis:
5. Newborn Screening Market - Asia Pacific Market Analysis
5.1 Asia Pacific Newborn Screening Market Revenue (US$ Mn), 2022 - 2030
6. Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 - by Product Type
6.1 Overview
6.2 Asia Pacific Newborn Screening Market Revenue Share, by Product Type, 2022 & 2030 (%)
6.3 Reagents and Assay Kits
6.3.1 Overview
6.3.2 Reagents and Assay Kits: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Asia Pacific Newborn Screening Market, by Reagents and Assay Kits, 2020-2030 (US$ Million)
6.4 Instruments
6.4.1 Overview
6.4.2 Instruments: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Asia Pacific Newborn Screening Market, by Instruments, 2020-2030 (US$ Million)
7. Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 - by Technology
7.1 Overview
7.2 Asia Pacific Newborn Screening Market Revenue Share, by Technology 2022 & 2030 (%)
7.3 Tandem Mass Spectrometry (TMS)
7.3.1 Overview
7.3.2 Tandem Mass Spectrometry (TMS): Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Molecular Assays
7.4.1 Overview
7.4.2 Molecular Assays: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Immunoassays and Enzymatic Assays
7.5.1 Overview
7.5.2 Immunoassays and Enzymatic Assays: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Pulse Oximetry Screening Technology
7.6.1 Overview
7.6.2 Pulse Oximetry Screening Technology: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Other Technologies
7.7.1 Overview
7.7.2 Other Technologies: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 - by Test Type
8.1 Overview
8.2 Asia Pacific Newborn Screening Market Revenue Share, by Test Type 2022 & 2030 (%)
8.3 Dry Blood Spot Test
8.3.1 Overview
8.3.2 Dry Blood Spot Test: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Hearing Screen Test
8.4.1 Overview
8.4.2 Hearing Screen Test: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Critical Congenital Heart Diseases (CCHD) Test
8.5.1 Overview
8.5.2 Critical Congenital Heart Diseases (CCHD) Test: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Other Test Types
8.6.1 Overview
8.6.2 Other Test Types: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 - by End User
9.1 Overview
9.2 Asia Pacific Newborn Screening Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals and Clinics
9.3.1 Overview
9.3.2 Hospitals and Clinics: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Diagnostic Laboratories
9.4.1 Overview
9.4.2 Diagnostic Laboratories: Asia Pacific Newborn Screening Market - Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Newborn Screening Market - Country Analysis
10.1 Asia Pacific Newborn Screening Market, Revenue and Forecast to 2030
10.1.1 Overview
10.1.2 Asia Pacific Newborn Screening Market, by Country
10.1.2.1 China
10.1.2.1.1 China Newborn Screening Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.1.2 China: Newborn Screening Market, by Product Type, 2020-2030 (US$ Million)
10.1.2.1.2.1 China: Newborn Screening Market, For Reagents and Assay Kits by Product Type, 2020-2030 (US$ Million)
10.1.2.1.2.2 China: Newborn Screening Market, For Instruments by Product Type, 2020-2030 (US$ Million)
10.1.2.1.3 China: Newborn Screening Market, by Technology, 2020-2030 (US$ Million)
10.1.2.1.4 China: Newborn Screening Market, by Test Type, 2020-2030 (US$ Million)
10.1.2.1.5 China: Newborn Screening Market, by End User, 2020-2030 (US$ Million)
10.1.2.2 Japan
10.1.2.2.1 Japan Newborn Screening Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.2.2 Japan: Newborn Screening Market, by Product Type, 2020-2030 (US$ Million)
10.1.2.2.2.1 Japan: Newborn Screening Market, For Reagents and Assay Kits by Product Type, 2020-2030 (US$ Million)
10.1.2.2.2.2 Japan: Newborn Screening Market, For Instruments by Product Type, 2020-2030 (US$ Million)
10.1.2.2.3 Japan: Newborn Screening Market, by Technology, 2020-2030 (US$ Million)
10.1.2.2.4 Japan: Newborn Screening Market, by Test Type, 2020-2030 (US$ Million)
10.1.2.2.5 Japan: Newborn Screening Market, by End User, 2020-2030 (US$ Million)
10.1.2.3 India
10.1.2.3.1 India Newborn Screening Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.3.2 India: Newborn Screening Market, by Product Type, 2020-2030 (US$ Million)
10.1.2.3.2.1 India: Newborn Screening Market, For Reagents and Assay Kits by Product Type, 2020-2030 (US$ Million)
10.1.2.3.2.2 India: Newborn Screening Market, For Instruments by Product Type, 2020-2030 (US$ Million)
10.1.2.3.3 India: Newborn Screening Market, by Technology, 2020-2030 (US$ Million)
10.1.2.3.4 India: Newborn Screening Market, by Test Type, 2020-2030 (US$ Million)
10.1.2.3.5 India: Newborn Screening Market, by End User, 2020-2030 (US$ Million)
10.1.2.4 Australia
10.1.2.4.1 Australia Newborn Screening Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.4.2 Australia: Newborn Screening Market, by Product Type, 2020-2030 (US$ Million)
10.1.2.4.2.1 Australia: Newborn Screening Market, For Reagents and Assay Kits by Product Type, 2020-2030 (US$ Million)
10.1.2.4.2.2 Australia: Newborn Screening Market, For Instruments by Product Type, 2020-2030 (US$ Million)
10.1.2.4.3 Australia: Newborn Screening Market, by Technology, 2020-2030 (US$ Million)
10.1.2.4.4 Australia: Newborn Screening Market, by Test Type, 2020-2030 (US$ Million)
10.1.2.4.5 Australia: Newborn Screening Market, by End User, 2020-2030 (US$ Million)
10.1.2.5 South Korea
10.1.2.5.1 South Korea Newborn Screening Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.5.2 South Korea: Newborn Screening Market, by Product Type, 2020-2030 (US$ Million)
10.1.2.5.2.1 South Korea: Newborn Screening Market, For Reagents and Assay Kits by Product Type, 2020-2030 (US$ Million)
10.1.2.5.2.2 South Korea: Newborn Screening Market, For Instruments by Product Type, 2020-2030 (US$ Million)
10.1.2.5.3 South Korea: Newborn Screening Market, by Technology, 2020-2030 (US$ Million)
10.1.2.5.4 South Korea: Newborn Screening Market, by Test Type, 2020-2030 (US$ Million)
10.1.2.5.5 South Korea: Newborn Screening Market, by End User, 2020-2030 (US$ Million)
10.1.2.6 Rest of Asia Pacific
10.1.2.6.1 Rest of Asia Pacific Newborn Screening Market Revenue and Forecast to 2030 (US$ Mn)
10.1.2.6.2 Rest of Asia Pacific: Newborn Screening Market, by Product Type, 2020-2030 (US$ Million)
10.1.2.6.2.1 Rest of Asia Pacific: Newborn Screening Market, For Reagents and Assay Kits by Product Type, 2020-2030 (US$ Million)
10.1.2.6.2.2 Rest of Asia Pacific: Newborn Screening Market, For Instruments by Product Type, 2020-2030 (US$ Million)
10.1.2.6.3 Rest of Asia Pacific: Newborn Screening Market, by Technology, 2020-2030 (US$ Million)
10.1.2.6.4 Rest of Asia Pacific: Newborn Screening Market, by Test Type, 2020-2030 (US$ Million)
10.1.2.6.5 Rest of Asia Pacific: Newborn Screening Market, by End User, 2020-2030 (US$ Million)
11. Asia Pacific Newborn Screening Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in Newborn Screening Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 LifeCell International Pvt Ltd
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Trivitron Healthcare Pvt Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 PerkinElmer Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Waters Corp
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Bio-Rad Laboratories Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Masimo Corp
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Natus Medical Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Medtronic Plc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療機器)の最新刊レポート

The Insight Partners社の医療機器分野での最新刊レポート


よくあるご質問


The Insight Partners社はどのような調査会社ですか?


The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/15 10:26

157.84 円

166.62 円

202.61 円

ページTOPに戻る